PARP-1 inhibition shows ameliorative effects in STZ-diabetic nephropathy [33], and, in line with this, the injection of nicotinamide or other PARP inhibitors, in parallel or prior to STZ administration, protects the beta cells against the toxic action of STZ, preventing the development of a diabetic state [34,35]. This evidence concerns the gene PARP1 and diabetic kidney disease.